Hodgkin lymphoma: exciting data at EHA and ASH 2019

Paul Jan Bröckelmann, MD, University Hospital of Cologne, Cologne, Germany, talks us through the key Hodgkin lymphoma data that was presented at EHA 2019, and any data to watch out for at this year's ASH meeting at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands. Dr Brockelmann specifically mentions the HD16 trial investigating radiotherapy consolidation therapy for the treatment of Hodgkin lymphoma, and the use of brentuximab vedotin in combination with nivolumab in pediatric and adolescent patients.